References
- Lucendo AJ, Molina‐Infante J, Arias Á, et al. Guidelines on eosinophilic esophagitis: evidence‐based statements and recommendations for diagnosis and management in children and adults. United European Gastroenterol J. 5(3): 335–358. 2017. https://doi.org/10.1177/2050640616689525. .
- Dellon ES, Liacouras CA, Molina-Infante J, et al. Updated international consensus diagnostic criteria for eosinophilic esophagitis: Proceedings of the AGREE Conference. Gastroenterology. 2018;155:1022–1033.e10.
- Lucendo AJ, Sanchez-Cazalilla M. Adult versus pediatric eosinophilic esophagitis: important differences and similarities for the clinician to understand. Expert Rev Clin Immunol. 2012;8(8):733–745.
- Molina-Infante J, Gonzalez-Cordero PL, Ferreira-Nossa HC, et al. Rising incidence and prevalence of adult eosinophilic esophagitis in midwestern Spain (2007–2016). United European Gastroenterol J. 2018;6(1):29–37. DOI:https://doi.org/10.1177/2050640617705913.
- Robson J, O’Gorman M, McClain A, et al. Incidence and prevalence of pediatric eosinophilic esophagitis in utah based on a 5-year population-based study. Clin Gastroenterol Hepatol. 2019;17(1):107–114.e1. DOI:https://doi.org/10.1016/j.cgh.2018.06.028.
- Arias Á, Lucendo AJ. Incidence and prevalence of eosinophilic oesophagitis increase continuously in adults and children in Central Spain: a 12-year population-based study. Dig Liver Dis. 2019;51(1):55–62.
- Dellon ES. Cost-effective care in eosinophilic esophagitis. Ann Allergy Asthma Immunol. 2019;123(2):166–172.
- Anderson J, Moonie S, Hogan MB, et al. Cost of chronic inflammatory disease: the impact of eosinophilic esophagitis in Nevada. journal of Digestive Diseases. 2020;21(1):12–19. DOI:https://doi.org/10.1111/1751-2980.12832.
- Eke R, Dellon ES. Hospitalization trends and determinants of inpatient costs for eosinophilic esophagitis patients in the United States: results from the nationwide inpatient sample analysis. Ann Gastroenterol. 2021;34(5):643–650.
- Melgaard D, Westmark S, Laurberg PT, et al. A diagnostic delay of 10 years in the DanEoE cohort calls for focus on education - a population-based cross-sectional study of incidence, diagnostic process and complications of eosinophilic oesophagitis in the North Denmark Region. United European Gastroenterol J. 2021;9(6):688–698. DOI:https://doi.org/10.1002/ueg2.12092.
- Lenti MV, Savarino E, Mauro A, et al. Diagnostic delay and misdiagnosis in eosinophilic oesophagitis. Dig Liver Dis. 2021;53(12):1632–1639. DOI:https://doi.org/10.1016/j.dld.2021.05.017. S1590-8658(21)00268-1
- Arias-González L, Rey-Iborra E, Ruiz-Ponce M, et al. Esophageal perforation in eosinophilic esophagitis: a systematic review on clinical presentation, management and outcomes. Dig Liver Dis. 2020;52(3):245–252. DOI:https://doi.org/10.1016/j.dld.2019.10.019.
- Gunasekaran TS, Berman J, Lim-Dunham JE. Esophageal perforation: an uncommon initial manifestation of eosinophilic esophagitis. Int J Pediatr Adolesc Med. 2016;3(3):123–127.
- Lucendo AJ, Friginal-Ruiz AB, Rodriguez B. Boerhaave’s syndrome as the primary manifestation of adult eosinophilic esophagitis. Two case reports and a review of the literature. Dis Esophagus. 2011;24(2):E11–15.
- Dellon ES, Hirano I. Epidemiology and natural history of eosinophilic esophagitis. Gastroenterology. 2018;154(2):319–332.e3.
- Lucendo AJ, Arias-González L, Molina-Infante J, et al. Determinant factors of quality of life in adult patients with eosinophilic esophagitis. United European Gastroenterol J. 2018;6(1):38–45. DOI:https://doi.org/10.1177/2050640617707095.
- Taft TH, Carlson DA, Simons M, et al. Esophageal hypervigilance and symptom-specific anxiety in patients with eosinophilic esophagitis. Gastroenterology. 2021;161(4):1133–1144. DOI:https://doi.org/10.1053/j.gastro.2021.06.023. S0016-5085(21)03137-1.
- de Rooij We, Bennebroek Evertsz’ F, Lei A, et al. Mental distress among adult patients with eosinophilic esophagitis. Neurogastroenterol Motil. 2021;33(7):e14069. DOI:https://doi.org/10.1111/nmo.14069.
- Reed CC, Corder SR, Kim E, et al. Psychiatric comorbidities and psychiatric medication use are highly prevalent in patients with eosinophilic esophagitis and associate with clinical presentation. Am J Gastroenterol. 2020;115(6):853–858. DOI:https://doi.org/10.14309/ajg.0000000000000597.
- Lucendo AJ, Arias-González L, Molina-Infante J, et al. Systematic review: health-related quality of life in children and adults with eosinophilic oesophagitis-instruments for measurement and determinant factors. Aliment Pharmacol Ther. 2017;46(4):401–409. DOI:https://doi.org/10.1111/apt.14194.
- Safroneeva E, Balsiger L, Hafner D, et al. Adults with eosinophilic oesophagitis identify symptoms and quality of life as the most important outcomes. Aliment Pharmacol Ther. 2018;48(10):1082–1090. DOI:https://doi.org/10.1111/apt.15000.
- Straumann A, Bauer M, Fischer B, et al. Idiopathic eosinophilic esophagitis is associated with a TH2-type allergic inflammatory response. J Allergy Clin Immunol. 2001;108(6):954–961. DOI:https://doi.org/10.1067/mai.2001.119917.
- Arias Á, Lucendo AJ. Molecular basis and cellular mechanisms of eosinophilic esophagitis for the clinical practice. Expert Rev Gastroenterol Hepatol. 2019;13(2):99–117.
- Rothenberg ME. Molecular, genetic, and cellular bases for treating eosinophilic esophagitis. Gastroenterology. 2015;148(6):1143–1157.
- Kelly KJ, Lazenby AJ, Rowe PC, et al. Eosinophilic esophagitis attributed to gastroesophageal reflux: improvement with an amino acid-based formula. Gastroenterology. 1995;109(5):1503–1512. DOI:https://doi.org/10.1016/0016-5085(95)90637-1.
- Molina-Infante J, Lucendo AJ. Dietary therapy for eosinophilic esophagitis. J Allergy Clin Immunol. 2018;142(1):41–47.
- Faubion WA, Perrault J, Burgart LJ, et al. Treatment of eosinophilic esophagitis with inhaled corticosteroids. J Pediatr Gastroenterol Nutr. 1998;27(1):90–93. DOI:https://doi.org/10.1097/00005176-199807000-00016.
- Chuang M-Y (Anthony), Chinnaratha MA, Hancock DG, et al. Topical steroid therapy for the treatment of eosinophilic esophagitis (EoE): a systematic review and meta-analysis. Clin Transl Gastroenterol. 6(3): e82. 2015. DOI:https://doi.org/10.1038/ctg.2015.9. .
- Greuter T, Bussmann C, Safroneeva E, et al. Long-term treatment of eosinophilic esophagitis with swallowed topical corticosteroids: development and evaluation of a therapeutic concept. Am J Gastroenterol. 112(10): 1527–1535. 2017. DOI:https://doi.org/10.1038/ajg.2017.202.
- Molina-Infante J, Bredenoord AJ, Cheng E, et al. Proton pump inhibitor-responsive oesophageal eosinophilia: an entity challenging current diagnostic criteria for eosinophilic oesophagitis. Gut. 65(3): 521–531. 2016. DOI:https://doi.org/10.1136/gutjnl-2015-310991.
- Spechler SJ, Genta RM, Souza RF. Thoughts on the complex relationship between gastroesophageal reflux disease and eosinophilic esophagitis. Am J Gastroenterol. 2007;102(6):1301–1306. DOI:https://doi.org/10.1111/j.1572-0241.2007.01179.x.
- Molina-Infante J, Lucendo AJ. Proton pump inhibitor therapy for eosinophilic esophagitis: a paradigm shift. Am J Gastroenterol. 2017;112(12):1770–1773.
- Lucendo AJ, Arias Á, Molina-Infante J. Efficacy of proton pump inhibitor drugs for inducing clinical and histologic remission in patients with symptomatic esophageal eosinophilia: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2016;14(1):13–22.e1. DOI:https://doi.org/10.1016/j.cgh.2015.07.041.
- Molina-Infante J, Rodriguez-Sanchez J, Martinek J, et al. Long-Term Loss of Response in Proton Pump Inhibitor-Responsive Esophageal Eosinophilia Is Uncommon and Influenced by CYP2C19 Genotype and Rhinoconjunctivitis. Am J Gastroenterol. 2015;110(11):1567–1575. DOI:https://doi.org/10.1038/ajg.2015.314.
- Gutiérrez-Junquera C, Fernández-Fernández S, Cilleruelo ML, et al. High prevalence of response to proton-pump inhibitor treatment in children with esophageal eosinophilia. J Pediatr Gastroenterol Nutr. 2016;62(5):704–710. DOI:https://doi.org/10.1097/MPG.0000000000001019.
- Gómez-Torrijos E, García-Rodríguez R, Castro-Jiménez A, et al. The efficacy of step-down therapy in adult patients with proton pump inhibitor-responsive oesophageal eosinophilia. Aliment Pharmacol Ther. 2016;43(4):534–540. DOI:https://doi.org/10.1111/apt.13496.
- Moawad FJ, Molina-Infante J, Lucendo AJ, et al. Systematic review with meta-analysis: endoscopic dilation is highly effective and safe in children and adults with eosinophilic oesophagitis. Aliment Pharmacol Ther. 2017;46(2):96–105. DOI:https://doi.org/10.1111/apt.14123.
- Lucendo AJ, Molina-Infante J. Esophageal dilation in eosinophilic esophagitis: risks, benefits, and when to do it. Curr Opin Gastroenterol. 2018;34(4):226–232.
- Attwood SEA, Smyrk TC, Demeester TR, et al. Esophageal eosinophilia with dysphagia. a distinct clinicopathologic syndrome. Dig Dis Sci. 1993;38(1):109–116. DOI:https://doi.org/10.1007/BF01296781.
- Straumann A, Spichtin HP, Bernoulli R, et al. [Idiopathic eosinophilic esophagitis: a frequently overlooked disease with typical clinical aspects and discrete endoscopic findings]. Schweiz Med Wochenschr. 1994;124(33):1419–1429.
- Schoepfer AM, Schürmann C, Trelle S, et al. Systematic review of outcome measures used in observational studies of adults with eosinophilic esophagitis. Int Arch Allergy Immunol. 2021;182(12):1169–1193. DOI:https://doi.org/10.1159/000516898.
- Hirano I, Chan ES, Rank MA, et al. AGA institute and the joint task force on allergy-immunology practice parameters clinical guidelines for the management of eosinophilic esophagitis. Gastroenterology. 2020;158(6):1776–1786. DOI:https://doi.org/10.1053/j.gastro.2020.02.038.
- Franciosi JP, Hommel KA, DeBrosse CW, et al. Development of a validated patient-reported symptom metric for pediatric eosinophilic esophagitis: qualitative methods. BMC Gastroenterol. 2011;11(1):126. DOI:https://doi.org/10.1186/1471-230X-11-126.
- Dellon ES, Irani A-M, Hill MR, et al. Development and field testing of a novel patient-reported outcome measure of dysphagia in patients with eosinophilic esophagitis. Aliment Pharmacol Ther. 2013;38(6):634–642. DOI:https://doi.org/10.1111/apt.12413.
- Schoepfer AM, Straumann A, Panczak R, et al. Development and validation of a symptom-based activity index for adults with eosinophilic esophagitis. Gastroenterology. 2014;147(6):1255–1266.e21. DOI:https://doi.org/10.1053/j.gastro.2014.08.028.
- Safroneeva E, Straumann A, Coslovsky M, et al. Symptoms have modest accuracy in detecting endoscopic and histologic remission in adults with eosinophilic esophagitis. Gastroenterology. 2016;150(3):581–590.e4. DOI:https://doi.org/10.1053/j.gastro.2015.11.004.
- Hudgens S, Evans C, Phillips E, et al. Psychometric validation of the dysphagia symptom questionnaire in patients with eosinophilic esophagitis treated with budesonide oral suspension. journal of Patient-Reported Outcomes. 2017;1(1):3. DOI:https://doi.org/10.1186/s41687-017-0006-5.
- Dellon ES, Collins MH, Katzka DA, et al. Improvements in dysphagia and pain with swallowing in patients with eosinophilic esophagitis receiving budesonide oral suspension. Clin Gastroenterol Hepatol. 2021;19(4):699–706.e4. DOI:https://doi.org/10.1016/j.cgh.2020.03.060.
- Martin LJ, Franciosi JP, Collins MH, et al. Pediatric eosinophilic esophagitis symptom scores (PEESS v2.0) identify histologic and molecular correlates of the key clinical features of disease. J Allergy Clin Immunol. 2015;135(6):1519–1528.e8. DOI:https://doi.org/10.1016/j.jaci.2015.03.004.
- Schoepfer AM, Panczak R, Zwahlen M, et al. How do gastroenterologists assess overall activity of eosinophilic esophagitis in adult patients? Am J Gastroenterol. 2015;110(3):402–414. DOI:https://doi.org/10.1038/ajg.2015.32.
- Lucendo AJ, Molina-Infante J. Limitation of symptoms as predictors of remission in eosinophilic esophagitis: the need to go beyond endoscopy and histology. Gastroenterology. 2016;150(3):547–549.
- Fontillon M, Lucendo AJ. Transmural eosinophilic infiltration and fibrosis in a patient with non-traumatic boerhaave’s syndrome due to eosinophilic Esophagitis. Am J Gastroenterol. 2012;107(11):1762.
- Kwiatek MA, Hirano I, Kahrilas PJ, et al. Mechanical properties of the esophagus in eosinophilic esophagitis. Gastroenterology. 2011;140(1):82–90. DOI:https://doi.org/10.1053/j.gastro.2010.09.037.
- Alexander R, Alexander JA, Ravi K, et al. Measurement of observed eating behaviors in patients with active and inactive eosinophilic esophagitis. Clin Gastroenterol Hepatol. 2019;17(11):2371–2373. DOI:https://doi.org/10.1016/j.cgh.2018.12.011.
- Taft TH, Guadagnoli L, Edlynn E. Anxiety and depression in eosinophilic esophagitis: a scoping review and recommendations for future research. J Asthma Allergy. 2019;12:389–399.
- Tajra JB, Calegaro JU, de Paula AP, et al. Correlation and concordance measures between clinical, endoscopic and histological scores activity in crohn’s disease under treatment. Scand J Gastroenterol. 2019;54(4):441–445. DOI:https://doi.org/10.1080/00365521.2019.1596305.
- Dellon ES, Speck O, Woodward K, et al. Distribution and variability of esophageal eosinophilia in patients undergoing upper endoscopy. Mod Pathol. 2015;28(3):383–390. DOI:https://doi.org/10.1038/modpathol.2014.110.
- Wolf WA, Cotton CC, Green DJ, et al. Evaluation of histologic cutpoints for treatment response in eosinophilic esophagitis. J Gastroenterol Hepatol Res. 2015;4(10):1780–1787. DOI:https://doi.org/10.17554/j.issn.2224-3992.2015.04.562.
- U.S. Department of Health and Human Services. Food and drug administration, center for drug evaluation and research (CDER). eosinophilic esophagitis: developing drugs for treatment guidance for industry [Internet]. 2020 [cited 2022 Jan 22]. Available from: https://www.fda.gov/media/120089/download
- Collins MH, Martin LJ, Alexander ES, et al. Newly developed and validated eosinophilic esophagitis histology scoring system and evidence that it outperforms peak eosinophil count for disease diagnosis and monitoring. Dis Esophagus. 2017;30(3):1–8. DOI:https://doi.org/10.1111/dote.12470.
- Warners MJ, Ambarus CA, Bredenoord AJ, et al. Reliability of histologic assessment in patients with eosinophilic oesophagitis. Aliment Pharmacol Ther. 2018;47(7):940–950. DOI:https://doi.org/10.1111/apt.14559.
- Ma C, Jairath V, Feagan BG, et al. Responsiveness of a histologic scoring system compared with peak eosinophil count in eosinophilic esophagitis. Am J Gastroenterol. 2022;117(2):264–271. DOI:https://doi.org/10.14309/ajg.0000000000001571.
- Lucendo AJ, Arias Á, Molina-Infante J, et al. The role of endoscopy in eosinophilic esophagitis: from diagnosis to therapy. Expert Rev Gastroenterol Hepatol. 2017;11(12):1135–1149. DOI:https://doi.org/10.1080/17474124.2017.1367664.
- Hirano I, Moy N, Heckman MG, et al. Endoscopic assessment of the oesophageal features of eosinophilic oesophagitis: validation of a novel classification and grading system. Gut. 2013;62(4):489–495. DOI:https://doi.org/10.1136/gutjnl-2011-301817.
- Gentile N, Katzka D, Ravi K, et al. Oesophageal narrowing is common and frequently under-appreciated at endoscopy in patients with oesophageal eosinophilia. Aliment Pharmacol Ther. 2014;40(11–12):1333–1340.
- van Rhijn BD, Verheij J, Smout AJPM, et al. The endoscopic reference score shows modest accuracy to predict histologic remission in adult patients with eosinophilic esophagitis. Neurogastroenterol Motil. 2016;28(11):1714–1722.
- Rodríguez-Sánchez J, Barrio-Andrés J, Nantes Castillejo O, et al. The endoscopic reference score shows modest accuracy to predict either clinical or histological activity in adult patients with eosinophilic oesophagitis. Aliment Pharmacol Ther. 2017;45(2):300–309.
- Hirano I, Spechler S, Furuta G, et al. White Paper AGA: drug development for eosinophilic esophagitis. Clin Gastroenterol Hepatol. 2017;15(8):1173–1183.
- Ma C, Schoepfer AM, Dellon ES, et al. Development of a core outcome set for therapeutic studies in eosinophilic esophagitis (COREOS). J Allergy Clin Immunol. 2022;149(2): 659–670. DOI:https://doi.org/10.1016/j.jaci.2021.07.001 ; . •• A consensus conference sough to develop a harmonized core outcome set (COS) of end points to be used to determine treatment efficacy in eosinophilic esophagitis (EoE). Using common outcomes measures in observational studies and controlled studies with pharmacologic and dietary interventions in patients of all ages with EoE will facilitate evidence synthesis and appraisal when comparing different treatments
- Furuta GT, Liacouras CA, Collins MH, et al. Eosinophilic esophagitis in children and adults: a systematic review and consensus recommendations for diagnosis and treatment. Gastroenterology. 133(4): 1342–1363. 2007. DOI:https://doi.org/10.1053/j.gastro.2007.08.017.
- Molina–Infante J, Ferrando–Lamana L, Ripoll C, et al. Esophageal eosinophilic infiltration responds to proton pump inhibition in most adults. Clin Gastroenterol Hepatol. 9(2): 110–117. 2011. DOI:https://doi.org/10.1016/j.cgh.2010.09.019.
- Liacouras CA, Furuta GT, Hirano I, et al. Eosinophilic esophagitis: updated consensus recommendations for children and adults. J Allergy Clin Immunol. 2011;128(1):3–20.e6. DOI:https://doi.org/10.1016/j.jaci.2011.02.040.
- Wen T, Dellon ES, Moawad FJ, et al. Transcriptome analysis of proton pump inhibitor–responsive esophageal eosinophilia reveals proton pump inhibitor–reversible allergic inflammation. J Allergy Clin Immunol. 2015;135(1):187–197. DOI:https://doi.org/10.1016/j.jaci.2014.08.043.
- Molina-Infante J, Rivas MD, Hernandez-Alonso M, et al. Proton pump inhibitor-responsive oesophageal eosinophilia correlates with downregulation of eotaxin-3 and Th2 cytokines overexpression. Aliment Pharmacol Ther. 2014;40(8):955–965. DOI:https://doi.org/10.1111/apt.12914.
- Lucendo AJ, Arias Á, Gonzalez-Cervera J, et al. Dual response to dietary/topical steroid and proton pump inhibitor therapy in adult patients with eosinophilic esophagitis. J Allergy Clin Immunol. 2016;137(3):931–934.e2. DOI:https://doi.org/10.1016/j.jaci.2015.07.033.
- Sodikoff J, Hirano I. Proton pump inhibitor–responsive esophageal eosinophilia does not preclude food-responsive eosinophilic esophagitis. J Allergy Clin Immunol. 2016;137(2):631–633.
- Tourlamain G, Garcia-Puig R, Gutiérrez-Junquera C, et al. Differences in management of eosinophilic esophagitis in Europe: an assessment of current practice. J Pediatr Gastroenterol Nutr. 2020; Jul;71(1):83–90. DOI:https://doi.org/10.1097/MPG.0000000000002672.
- Laserna-Mendieta EJ, Casabona S, Savarino E, et al. Efficacy of therapy for eosinophilic esophagitis in real-world practice. Clin Gastroenterol Hepatol. 2020;18(13):2903–2911.e4. DOI:https://doi.org/10.1016/j.cgh.2020.01.024.
- Hannan N, Steel A, McMillan SS, et al. Health service use and treatment choices for pediatric eosinophilic esophagitis: findings from a cross-sectional survey of Australian carers. Front Pediatr. 2020;8:147.
- van Rhijn Bd, Weijenborg PW, Verheij J, et al. Proton pump inhibitors partially restore mucosal integrity in patients with proton pump inhibitor–responsive esophageal eosinophilia but not eosinophilic esophagitis. Clin Gastroenterol Hepatol. 2014;12(11):1815–1823.e2. DOI:https://doi.org/10.1016/j.cgh.2014.02.037.
- Peterson KA, Thomas KL, Hilden K, et al. Comparison of esomeprazole to aerosolized, swallowed fluticasone for eosinophilic esophagitis. Dig Dis Sci. 2010;55(5):1313–1319. DOI:https://doi.org/10.1007/s10620-009-0859-4.
- Moawad FJ, Veerappan GR, Dias JA, et al. Randomized controlled trial comparing aerosolized swallowed fluticasone to esomeprazole for esophageal eosinophilia. Am J Gastroenterol. 2013;108(3):366–372. DOI:https://doi.org/10.1038/ajg.2012.443.
- Lucendo A, Santander C, Savarino E, et al. EoE CONNECT, the European registry of clinical, environmental, and genetic determinants in eosinophilic esophagitis: rationale, design, and study protocol of a large-scale epidemiological study in Europe. Ther Adv Gastroenterol. 2022;15:1–16.
- Frandsen LT, Westmark S, Melgaard D, et al. Effectiveness of PPI treatment and guideline adherence in 236 patients with eosinophilic oesophagitis—results from the population-based DanEoE cohort shows a low complication rate. United European Gastroenterol J. 2021;9(8):910–918. DOI:https://doi.org/10.1002/ueg2.12146.
- Navarro P, Laserna-Mendieta EJ, Guagnozzi D, et al. Proton pump inhibitor therapy reverses endoscopic features of fibrosis in eosinophilic esophagitis. Dig Liver Dis. 2021;53(11):1479–1485. DOI:https://doi.org/10.1016/j.dld.2021.05.025.
- Nassar Y, Richter S. Proton-pump inhibitor use and fracture risk: an updated systematic review and meta-analysis. journal of Bone metabolism. 2018;25(3):141–151.
- Sun J, Sun H, Cui M, et al. The use of anti-ulcer agents and the risk of chronic kidney disease: a meta-analysis. Int Urol Nephrol. 2018;50(10):1835–1843. DOI:https://doi.org/10.1007/s11255-018-1908-8.
- Vaezi MF, Yang Y-X, Howden CW. Complications of proton pump inhibitor therapy. Gastroenterology. 2017;153(1):35–48.
- Attwood SE, Ell C, Galmiche JP, et al. Long-term safety of proton pump inhibitor therapy assessed under controlled, randomised clinical trial conditions: data from the SOPRAN and LOTUS studies. Aliment Pharmacol Ther. 2015;41(11):1162–1174. DOI:https://doi.org/10.1111/apt.13194.
- Martinucci I, Blandizzi C, Bodini G, et al. Vonoprazan fumarate for the management of acid-related diseases. Expert Opin Pharmacother. 2017;18(11):1145–1152. DOI:https://doi.org/10.1080/14656566.2017.1346087.
- Ghisa M, Barberio B, Savarino V, et al. Vonoprazan may provide better results than PPIs in helicobacter pylori eradication and beyond – is it time for a change? J Gastrointestin Liver Dis. 2019;28(4):375–377. DOI:https://doi.org/10.15403/jgld-573.
- Kuzumoto T, Tanaka F, Sawada A, et al. Vonoprazan shows efficacy similar to that of proton pump inhibitors with respect to symptomatic, endoscopic, and histological responses in patients with eosinophilic esophagitis. Esophagus. 2021;18(2):372–379. DOI:https://doi.org/10.1007/s10388-020-00783-0.
- Okimoto E, Ishimura N, Ishihara S. Clinical characteristics and treatment outcomes of patients with eosinophilic esophagitis and eosinophilic gastroenteritis. Digestion. 2021;102(Suppl. 1):33–40.
- Alexander JA, Jung KW, Arora AS, et al. Swallowed fluticasone improves histologic but not symptomatic response of adults with eosinophilic esophagitis. Clin Gastroenterol Hepatol. 2012;10(7):742–749.e1. DOI:https://doi.org/10.1016/j.cgh.2012.03.018.
- Lucendo AJ, Pascual-Turrion JM, Navarro M, et al. Endoscopic, bioptic, and manometric findings in eosinophilic esophagitis before and after steroid therapy: a case series. Endoscopy. 2007;39(9):765–771. DOI:https://doi.org/10.1055/s-2007-966738.
- Bergquist H, Larsson H, Johansson L, et al. Dysphagia and quality of life may improve with mometasone treatment in patients with eosinophilic esophagitis: a pilot study. Otolaryngol Head Neck Surg. 2011;145(4):551–556. DOI:https://doi.org/10.1177/0194599811409857.
- Rank MA, Sharaf RN, Furuta GT, et al. Technical review on the management of eosinophilic esophagitis: a report from the AGA institute and the joint task force on allergy-immunology practice parameters. Ann Allergy Asthma Immunol. 2020;124(5):424–440.e17. DOI:https://doi.org/10.1016/j.anai.2020.03.021.
- Murali AR, Gupta A, Attar BM, et al. Topical steroids in eosinophilic esophagitis: systematic review and meta-analysis of placebo-controlled randomized clinical trials. J Gastroenterol Hepatol. 2016;31(6):1111–1119. DOI:https://doi.org/10.1111/jgh.13281.
- Hao L-X, Lu Y, Li T, et al. A meta-analysis of efficacy of topical steroids in eosinophilic esophagitis: from the perspective of histologic, clinical, and endoscopic outcome. Gastroenterol Hepatol. 2021;44(4):251–260. DOI:https://doi.org/10.1016/j.gastrohep.2020.07.010.
- Dohil R, Newbury R, Fox L, et al. Oral viscous budesonide is effective in children with eosinophilic esophagitis in a randomized, placebo-controlled trial. Gastroenterology. 2010;139(2):418–429. DOI:https://doi.org/10.1053/j.gastro.2010.05.001.
- Hefner JN, Howard RS, Massey R, et al. A randomized controlled comparison of esophageal clearance times of oral budesonide preparations. Dig Dis Sci. 2016;61(6):1582–1590. DOI:https://doi.org/10.1007/s10620-015-3990-4.
- Rubinstein E, Lee JJ, Fried A, et al. Comparison of 2 delivery vehicles for viscous budesonide to treat eosinophilic esophagitis in children. J Pediatr Gastroenterol Nutr. 2014;59(3):317–320. DOI:https://doi.org/10.1097/MPG.0000000000000436.
- Lee J, Shuker M, Brown-Whitehorn T, et al. Oral viscous budesonide can be successfully delivered through a variety of vehicles to treat eosinophilic esophagitis in children. J Allergy Clin Immunol Pract. 2016;4(4):767–768. DOI:https://doi.org/10.1016/j.jaip.2016.02.005.
- Dellon ES, Sheikh A, Speck O, et al. Viscous topical is more effective than nebulized steroid therapy for patients with eosinophilic esophagitis. Gastroenterology. 143(2): 321–324.e1. 2012. DOI:https://doi.org/10.1053/j.gastro.2012.04.049.
- Dellon ES, Katzka DA, Collins MH, et al. Budesonide oral suspension improves symptomatic, endoscopic, and histologic parameters compared with placebo in patients with eosinophilic esophagitis. Gastroenterology. 2017;152(4):776–786.e5. DOI:https://doi.org/10.1053/j.gastro.2016.11.021.
- Hirano I, Collins MH, Katzka DA, et al. Budesonide oral suspension improves outcomes in patients with eosinophilic esophagitis: results from a phase 3 trial. Clin Gastroenterol Hepatol. 2022;20(3): 525–534. DOI:https://doi.org/10.1016/j.cgh.2021.04.022
- Takeda Receives Complete Response Letter from the U.S. FDA for TAK-721 [Internet]. [cited 2022 Jan 31]. Available from: https://www.takeda.com/newsroom/newsreleases/2021/takeda-receives-complete-response-letter-from-the-us-fda-for-tak-721/
- Ketchem CJ, Reed CC, Stefanadis Z, et al. Treatment with compounded fluticasone suspension improves the clinical, endoscopic, and histologic features of eosinophilic esophagitis. Dis Esophagus. 2021;34(7):doaa120. DOI:https://doi.org/10.1093/dote/doaa120.
- Syverson EP, Hait E, McDonald DR, et al. Oral viscous mometasone is an effective treatment for eosinophilic esophagitis. J Allergy Clin Immunol Pract. 2020;8(3):1107–1109. DOI:https://doi.org/10.1016/j.jaip.2019.08.042.
- Casiraghi A, Gennari CG, Musazzi UM, et al. Mucoadhesive budesonide formulation for the treatment of eosinophilic esophagitis. Pharmaceutics. 2020;12(3):E211. DOI:https://doi.org/10.3390/pharmaceutics12030211.
- Miehlke S, Lucendo AJ, Straumann A, et al. Orodispersible budesonide tablets for the treatment of eosinophilic esophagitis: a review of the latest evidence. Therap Adv Gastroenterol. 2020;13:175628482092728.
- Lucendo AJ, Miehlke S, Schlag C, et al. Efficacy of budesonide orodispersible tablets as induction therapy for eosinophilic esophagitis in a randomized placebo-controlled trial. Gastroenterology. 2019;157(1):74–86.e15. DOI:https://doi.org/10.1053/j.gastro.2019.03.025. .
- Straumann A, Lucendo AJ, Miehlke S, et al. Budesonide orodispersible tablets maintain remission in a randomized, placebo-controlled trial of patients with eosinophilic esophagitis. Gastroenterology. 2020;159(5):1672–1685. DOI:https://doi.org/10.1053/j.gastro.2020.07.039.
- Hirano I, Safroneeva E, Roumet MC, et al. Randomised clinical trial: the safety and tolerability of fluticasone propionate orally disintegrating tablets versus placebo for eosinophilic oesophagitis. Aliment Pharmacol Ther. 2020;51(8):750–759. DOI:https://doi.org/10.1111/apt.15670.
- Hirano I, Lucendo A, Schlag C, et al. Fluticasone propionate orally disintegrating tablet (APT-1011) for eosinophilic esophagitis: randomized controlled trial. Clin Gastroenterol Hepatol. 2022. DOI:https://doi.org/10.1016/j.cgh.2022.02.013.
- Rosenbaum C, Grimm M, Krause J, et al. Functionality and acceptance of the esocap system-A novel film-based drug delivery technology: results of an in vivo study. Pharmaceutics. 2021;13(6):828. DOI:https://doi.org/10.3390/pharmaceutics13060828.
- Lucendo AJ, López-Sánchez P. Targeted therapies for eosinophilic gastrointestinal disorders. BioDrugs. 2020;34(4):477–493.
- Tamarit-Sebastian S, Ferrer-Soler FM, Lucendo AJ. Current options and investigational drugs for the treatment of eosinophilic esophagitis. Expert Opin Investig Drugs. 2022;31(2):193–210. DOI:https://doi.org/10.1080/13543784.2022.2033207.
- McBrien CN, Menzies-Gow A. The biology of eosinophils and their role in asthma. Front Med (Lausanne). 2017;4:93.
- Hirano I, Collins MH, Assouline-Dayan Y, et al. RPC4046, a monoclonal antibody against il13, reduces histologic and endoscopic activity in patients with eosinophilic esophagitis. Gastroenterology. 2019;156(3):592–603.e10. DOI:https://doi.org/10.1053/j.gastro.2018.10.051.
- Vatrella A, Fabozzi I, Calabrese C, et al. Dupilumab: a novel treatment for asthma. J Asthma Allergy. 2014;7:123–130.
- Hirano I, Dellon ES, Hamilton JD, et al. Efficacy of dupilumab in a phase 2 randomized trial of adults with active eosinophilic esophagitis. Gastroenterology. 2020;158(1):111–122.e10. DOI:https://doi.org/10.1053/j.gastro.2019.09.042.
- Dellon ES. Dupilumab for EoE at ACG 2021 [Internet]. 2021 [cited 2021 Oct 21]. Available from: https://www.hcplive.com/view/dellon-dupilumab-eoe-acg-2021
- Kiwamoto T, Kawasaki N, Paulson JC, et al. Siglec-8 as a drugable target to treat eosinophil and mast cell-associated conditions. Pharmacol Ther. 2012;135(3):327–336. DOI:https://doi.org/10.1016/j.pharmthera.2012.06.005.
- Dellon ES, Peterson KA, Murray JA, et al. Anti-siglec-8 antibody for eosinophilic gastritis and duodenitis. N Engl J Med. 2020;383(17):1624–1634. DOI:https://doi.org/10.1056/NEJMoa2012047.
- Bryan AM, Del Poeta M. Sphingosine-1-phosphate receptors and innate immunity. Cell Microbiol. 2018;20(5):e12836.
- Pérez-Jeldres T, Alvarez-Lobos M, Rivera-Nieves J. Targeting sphingosine-1-phosphate signaling in immune-mediated diseases: beyond multiple sclerosis. Drugs. 2021;81(9):985–1002.
- Votto M, De Filippo M, Castagnoli R, et al. Non-invasive biomarkers of eosinophilic esophagitis. Acta Biomed. 2021;92(S7):e2021530. DOI:https://doi.org/10.23750/abm.v92iS7.12401.
- Lucendo AJ, Castillo P, Martin-Chavarri S, et al. Manometric findings in adult eosinophilic oesophagitis: a study of 12 cases. Eur J Gastroenterol Hepatol. 2007;19(5):417–424. DOI:https://doi.org/10.1097/MEG.0b013e328010bd69.
- Visaggi P, Ghisa M, Barberio B, et al. Systematic review: esophageal motility patterns in patients with eosinophilic esophagitis. Dig Liver Dis. 2022; DOI: https://doi.org/10.1016/j.dld.2022.01.003. S1590-8658(22)00004-4.
- Rokkas T, Niv Y, Malfertheiner P. A network meta-analysis of randomized controlled trials on the treatment of eosinophilic esophagitis in adults and Children. J Clin Gastroenterol. 2021;55(5):400–410. DOI:https://doi.org/10.1097/MCG.0000000000001356.
- Beauchemin C, Castonguay A, Chan ES, et al. Economic evaluation of budesonide orodispersible tablets for the treatment of eosinophilic esophagitis: a cost–utility analysis. Adv Ther. 2021;38(12):5737–5751.
- Greuter T, Safroneeva E, Bussmann C, et al. Maintenance treatment of eosinophilic esophagitis with swallowed topical steroids alters disease course over A 5-year follow-up period in adult patients. Clin Gastroenterol Hepatol. 2019;17(3):419–428.
- Greuter T, Godat A, Ringel A, et al. Effectiveness and safety of high- vs low-dose swallowed topical steroids for maintenance treatment of eosinophilic esophagitis: a multicenter observational study. Clin Gastroenterol Hepatol. 2021;19(12):2514–2523.
- Mehta P, Pan Z, Skirka S, et al. Medication adherence aligns with age and a behavioral checklist but not symptoms or quality of life for patients with eosinophilic esophagitis. J Pediatr. 2021;235:246–252.
- Mehta P, Pan Z, Furuta GT, et al. Mobile health tool detects adherence rates in pediatric patients with eosinophilic esophagitis. J Allergy Clin Immunol Pract. 2019;7(7):2437–2439. DOI:https://doi.org/10.1016/j.jaip.2019.03.016.
- Drosos AA, Pelechas E, Kaltsonoudis E, et al. Biologic Therapies and Autoimmune Phenomena. mediterranean Journal of Rheumatology. 2021;32(2):96–103. DOI:https://doi.org/10.31138/mjr.32.2.96.
- Patel SV, Khan DA. Adverse reactions to biologic therapy. Immunol Allergy Clin North Am. 2017;37(2):397–412.